LOGIN  |  REGISTER
Chimerix
Compass Therapeutics

R1 RCM to Present at Upcoming Investor Conferences

May 02, 2023 | Last Trade: US$14.07 0.01 -0.07

MURRAY, Utah, May 02, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at two upcoming conferences:

  • The Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10 at 10:00am PT
  • The 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16 at 9:00am ET

A live audio webcast of the presentation will be available on the Investor Relations section of R1’s website at ir.r1rcm.com. A replay of the webcast will be available for 90 days following the live webcast.

About R1 RCM

R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. R1’s proven and scalable operating models seamlessly complement a healthcare organization’s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience. To learn more, visit: r1rcm.com.

Contact:
R1 RCM Inc.
Investor Relations:
Atif Rahim
312.324.5476
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Relations:
Allison+Partners for R1RCM
Amanda Critelli
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB